Table1_Multisystem inflammatory syndrome drug treatment in countries with different income profiles: a scoping review.XLSX

Objective: The purpose of this study was to map and describe the studies that have investigated therapeutic alternatives for the management of paediatric multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. Considering the origin of the studies performed (low-, middle- and high-income countries), a systematic scoping review was conducted with primary studies that reported the use of medications for the treatment of patients with MIS-C.
Sources: The searches were performed in MEDLINE, Embase, Lilacs, Epistemonikos, CINAHL, and CENTRAL, in the grey literature (theses and dissertations from CAPES, ProQuest, and PROSPERO) and in clinical trial databases until May 2022. The selection and extraction of studies were performed independently by two reviewers.
Summary of the findings: A total of 173 studies were included, most of which were published as case reports or series. No randomized controlled clinical trials (RCTs) were identified. The investigated drugs were immunoglobulins, glucocorticoids, monoclonal antibodies, anticoagulants, and antiplatelet agents.
Conclusion: The dosages, when reported, were heterogeneous among the studies. The ethnicity and comorbidity of the participants were poorly reported. Monoclonal antibodies, drugs with higher costs, were mostly described in studies of high-income countries.

研究目的：本研究旨在系统梳理并描述针对与新型冠状病毒肺炎（COVID-19）相关的儿童多系统炎症综合征（Multisystem Inflammatory Syndrome in Children, MIS-C）的治疗替代方案相关研究。考虑到研究开展所在国家的收入层级（低收入、中等收入与高收入国家），本研究针对报道了MIS-C患者药物治疗方案的原始研究，开展了系统性范围综述（systematic scoping review）。
检索资源：本研究检索了MEDLINE、Embase、Lilacs、Epistemonikos、CINAHL及CENTRAL数据库，同时检索了灰色文献（CAPES、ProQuest与PROSPERO收录的学位论文）及临床试验数据库，检索时限截至2022年5月。研究筛选与数据提取工作由两名评审员独立完成。
研究结果概述：最终纳入173项研究，其中大部分为病例报告或病例系列研究。未检索到随机对照临床试验（Randomized Controlled Trial, RCT）。所涉及的治疗药物包括免疫球蛋白、糖皮质激素、单克隆抗体、抗凝剂与抗血小板药物。
研究结论：现有研究中报道的药物剂量存在显著异质性；受试者的种族与共病情况报道严重不足。单克隆抗体这类高成本药物，在高收入国家的相关研究中占比更高。